The natriuretic effect of DA-1 agonists is less in the spontaneously hypertensive rat (SHR) than its normotensive control, the Wistar-Kyoto rat (WKY). To determine a mechanism of the decreased effect of DA-1 agonists on sodium transport, DA-1 receptors in renal proximal convoluted tubule (PCI) were studied by radioligand binding and by adenylate cyclase (AC) determinations. Specific binding of '25I-SCH 23982 (defined by 10 MM SCH 23390, a DA-1 antagonist) was concentration dependent, saturable, and stereoselective. The dissociation constant, maximum receptor density, and DA-1 antagonist inhibition constant were similar in SHR and WKY. The apparent molecular weight of the DA-1 receptor determined by the photoaffinity D1 probe '25I-MAB was also similar in WKY and SHR. However, DA-1 agonists competed more effectively for specific '25I-SCH 23982 binding sites in WKY than in SHR.
Introduction
It has been suggested that nonneuronal dopamine produced locally in the kidney (1-5) acts as a paracrine or autocrine substance causing an inhibition of sodium transport (3, 5-8, 8a ). The enzymes necessary to synthesize dopamine are found in the kidney (9) ; aromatic L-amino acid decarboxylase, which converts L-DOPA to dopamine, seems to be mainly located around the apical cell membrane (5) ofthe S 1 and S2 segments of the renal proximal tubule (10) . Dopamine produced in the proximal convoluted tubule (PCT)1 (1, 5, 10, 11) Receivedfor publication 12 April 1989 and in revisedform 10 July 1989. Na+ transport in part by occupation ofthe DA-1 receptor (6-8, 11, 12) . The dopamine-regulated sodium transport in PCT may be mediated by inhibition of Na+/K+ ATPase (1, 5, 1 1-13) and Na+/H+ antiport activities (14) . The latter effect may be mediated by stimulation of adenylate cyclase (AC) activity (14) . Dopamine and DA-1 agonists may also decrease sodium transport in nephron segments beyond the proximal tubule (15) , including the cortical collecting duct (16) . We have previously reported the presence of DA-1 receptors coupled to stimulation of adenylate cyclase in the PCT of the rabbit ( 17) and rat kidney ( 18) . These receptors are also present in proximal straight tubule (17) (18) (19) (20) and cortical collecting duct (16, 19) .
Abnormalities in the renal dopaminergic system have been reported in genetically hypertensive rat including the spontaneously hypertensive rat (SHR) of the Okamoto Aoki strain (21) (22) (23) (24) (25) (26) . The natriuretic effects of DA-l agonists (25, 26) and the antinatriuretic effects of a DA-1 antagonist (6) are reduced in the SHR. These experiments were therefore designed to determine if there are differences in DA-1 receptor density or affinity and/or AC activity in PCT of SHR and Wistar-Kyoto rat (WKY). The microdissected PCT was chosen because the study ofwhole renal homogenates may obscure the presence of biochemical defects in specific nephron segments.
Methods

Dissection ofproximal convoluted tubules
PCT was microdissected from male 18-20-wk-old SHR (mean arterial pressure 166.6±2.7 mmHg, n = 9) and WKY (mean arterial pressure 11 1.3±1.5 mmHg, n = 9) (Harlan-Sprague Dawley, Inc., Indianapolis, IN) according to the procedure previously described from this laboratory (17, 18) . In a separate group of experiments 3-wk-old WKY and SHR were used. The rats were maintained on a standard rat chow with ad lib. access to water. After the rats were killed by decapitation, the descending aorta was cannulated with PE-90 polyethylene tubing, and the kidneys were perfused via a peristaltic pump (WIZ; Isco Inc., Lincoln, NE). The perfusate consisted of a calcium-free Dulbecco's PBS, pH 7.4 (Gibco Laboratories, Grand Island, NY) containing collagenase, 200 mg/dl (Type IV, Sigma C-5831; Sigma Chemical Co., St. Louis, MO) and glucose (1 g/liter), at 250C. After perfusing the kidney with the collagenase solution, the cortical tissue was sliced into 0.5-mm sections followed by incubation in calcium-free Dulbecco's buffer, pH 7.4, at 37'C for 0-15 min. Incubation time varied from lot to lot of collagenase. After two quick rinses with ice-cold Dulbecco's buffer the tissues were transferred into Petri dishes with ice-cold Dulbecco's buffer containing glucose (1 g/liter), 200 ,uM vitamin E (Trolox 0671 8JM; Aldrich Chemical Co., Milwaukee, WI) and 1 mM ascorbic acid (A-0278; Sigma Chemical Co.). Dissection was performed at 4°C under a Wild stereozoom microscope with dark-field illumination as previously described (17) . PCT (SI and S2) was microdissected manually. The PCT was identified by an attached glomerulus and its location in the renal labyrinth and milky appearance (27) .
Quantitative autoradiographic studies ofmicrodissected nephrons
After microdissection, the tubules were transferred in 5 Ml of microdissection solution (Dulbecco's buffer without collagenase) onto cold glass slides (teflon-coated microscope slides, Cel-Line Associates Inc., Newfield, NJ) for autoradiographic studies. The glass slides were prepared for binding studies by cleaning with 1% hydrochloric acid followed by dipping in deionized H20. The glass slides were coated with 0.1% (wt/vol in water) poly-D-lysine hydrobromide (Sigma P-1524).
The nephron segments were air dried on the poly-D-lysine coated slides and stored frozen with desiccant at -80'C for at least 24 h. Tubular length was measured with a reticle attachment to the stereomicroscope. All tubular length measurements are reported in unstretched lengths. We found greater reproducibility in PCT measurement using unstretched length as compared to stretched length when length was correlated with protein content determined by the method ofLowry et al. (28) (r = 0.98 unstretched vs. protein content, r = 0.82 stretched vs. protein content).
Saturation studies. Desiccated tubules were preincubated for 5 min in a calcium-free Dulbecco's PBS (pH 7.4) containing glucose (1 g/ liter), at room temperature. The tubules were then incubated in the same buffer with varying concentrations of I251-SCH-23982 (New England Nuclear, Boston, MA) ranging from 3.25 to 50 nM. This concentration range was previously found to be optimal for DA-1 receptors in the rat renal cortex (29 (17, 18) . Deionized water (20 Ml), with and without various drugs to be tested were added to each tube. The reaction was started by placing the tubes in a 370C shaking water bath for 20 min. The incubation was terminated by boiling the tubes for 5 min. Ice-cold sodium acetate buffer (400 M1, 5 mM, pH 4.75) was added to each tube. Thereafter, 50
Ml of the samples were added to 200 Ml of antibody solution (10 Ml of antibody brought up to 500 ml of 50 mM sodium acetate with 5 mg/ml BSA). Trace '251-cAMP (50yMl = 10,000 cpm) was added to each tube and then the tubes were incubated for 12-24 h at 4VC. 700 Ml of Staphylococcus aureus (Staphylococcus aureus solution: 50 mM sodium acetate; 1:11 vol/vol, Sigma catalogue S-2014) was added to each tube. After I h incubation, the tubes were centrifuged at 3,000 rpm for 10 min and the gamma emissions in the precipitates were measured in a gamma counter. The antagonists used in these studies were the DA-I
antagonist SCH-23390, and beta adrenergic antagonist (-)-propranolol. The selective DA-l agonists used were fenoldopam, SKF-38393, and SND-919-C 12.
Photoaffinity labeling ofthe DA-J receptor
Microdissected PCT were labeled with the D-1 dopamine specific photoaffinity probe, '25I-MAB, with modification of the previously described procedure (31). 2 cm of PCT from both the WKY and SHR were suspended in two separate tubes (1 cm each) in 1.0 ml assay buffer (25 mM Tris-HCI, 100 mM NaCl, pH 7.4, and the following protease inhibitors: 1 mM EDTA, 0.5 mM PMSF, 5 Ag/ml leupeptin, and 5 Mg/ml pepstatin). The PCT suspensions were incubated in the dark for 90 min at 250C in the presence or absence SCH-23390 (10 MM) to determine nonspecific binding or total binding, respectively. After incubation the samples were centrifuged at 15,000 g (20 min, 4C). The pellets were then washed with 1.2 ml of buffer (25 mM Tris-HCl, pH 7.4, 100 mM NaCl, protease inhibitors and 0.5% BSA) and then recentrifuged. The pellets were resuspended in 0.2 ml of the Tris buffer (without BSA) and illuminated with ultraviolet light from a hand-held (model ENF 28; Spectronics Corp.) ultraviolet lamp (254 nm) for 35 s at 4°C. The samples were then diluted with 1 ml of 25 mM Tris buffer (without BSA), recentrifuged, and prepared for SDS-PAGE as described below. The photoaffinity labeled PCT samples were washed once with 25 mM Tris buffer and suspended in 100 ML of SDS-PAGE buffer (25 mM Tris-HCl, pH 6.8, 10% SDS, 10% glycerol, and 5% beta-mercaptoethanol with proteolytic enzyme inhibitors). After an overnight incubation at 220C, the SDS-solubilized samples were subjected to electrophoresis on polyacrylamide slab gels; a 4.5% upper stacking gel and 10% separating gel were used. After completion of the electrophoresis, the gel was dried using a slab gel drier (model 224; Bio-Rad Laboratories, Richmond, CA) and autoradiographed at -80°C with Kodak XAR-5 film.
Statistical analyses. The results are expressed as mean±SE. The dissociation constant (Kd), maximum receptor density (Bmax), and inhibition constants (K,) were calculated using nonlinear regression (Lundon 1,2; Lundon Software, Inc., Cleveland, OH). Significant differences (P < 0.05) were determined using a paired t test when two groups were compared and ANOVA for repeated measures, Scheffe's test was used when more than two groups were compared.
Results
Radioligand binding studies Saturation studies. The specific binding of '25I-SCH 23982 reached steady state in the rat PCT after 30 min (data not shown). Scatchard plots were linear, similar to our previous findings (18, 29) (Fig. 1) . Specific binding (55% at Kd) of 1251.
SCH-23982 to rat PCT was concentration dependent and saturable in both WKY and SHR (Fig. 1, insets) Competition studies. The DA-l antagonist SCH-23390 was more effective than its inactive isomer SCH-23388 in competing for specific '25I-SCH-23982 binding sites, indicating stereoselectivity in both WKY and SHR (Fig. 2) (32) . The DA-1 agonist, fenoldopam (100 nM and 10 ,M) increased AC activity in PCT of the WKY (n = 5). In contrast, in the PCT of SHR, fenoldopam (100 nM) had little effect on AC activity (Fig. 3) . In a separate group of experiments, fenoldopam-stimulated AC activity in the PCT of WKY was blocked by the DA-1 antagonist, SCH-23390 (n = 6) but not by the beta adrenergic antagonist (-)-propranolol (n = 6) demonstrating specificity (Fig. 4) . In this series of experiments a modest but significant increase over basal AC activity was measured in the SHR. (Fig. 5) .
Effect offorskolin andparathyroid hormone on AC activity.
To determine whether the inability of DA-1 agonists to stimulate PCT AC activity in SHR was a generalized defect of the AC enzyme in the PCT, we studied other drugs (parathyroid hormone and forskolin), which are known to stimulate AC. Under the same experimental conditions forskolin and parathyroid hormone stimulated AC activity in PCT of WKY and SHR (Fig. 5) to a similar extent as that found by other investigators (33) . Thus the DA-1 stimulated AC defect in the SHR may be selective to the DA-1 system.
Effect ofguanine nucleotides on AC activity. To determine the influence of G proteins on DA-l -stimulated AC activity, (Fig. 6) . The increase in AC activity elicited by Gpp(NH)p was greater than that found for GTP.
The ability of the selective DA-1 agonist, SND 919-C 12, to stimulate AC activity was increased by both GTP and Gpp(NH)p in WKY similar to that reported for other D, receptors (34) . In the SHR, however, SND failed to increase the stimulation of AC activity by either GTP or Gpp(NH)p (Fig. 7) . Fenoldopam stimulated AC activity in the 3-wk-old WKY and SHR. To determine if the DA-l AC coupling defect was present before the onset of hypertension, we measured fenoldopam stimulated AC activity in the PCT of 3-wk-old WKY and SHR (Table II) . The DA-1 agonist stimulated AC activity in PCT of WKY as early as 3 wk of age; the stimulatory effect was greater at 18-22 wk. In contrast, no such stimulatory effect was noted in SHR at either age group.
Photoaffinity labeling ofthe DA-J receptor Fig. 8, A and B shows the results obtained when kidney tubules and striatum were incubated with '251-MAB, photolyzed, and subjected to SDS-PAGE. Striatal tissue from the WKY was included as a control (Fig. 8 B) . Analysis of the migration 2 distance of the labeled bands relative to proteins of known molecular weight showed that the photoaffinity probe was specifically incorporated into a diffuse polypeptide band of apparent molecular weight of 74,000 D in both the PCT and striatum. In the kidney two minor bands, with apparent molecular weights of 50,000 and 32,000 D were also present in the WKY.
In the SHR only the 32,000-D band was discernable in the kidney. The striatum also demonstrated a 74,000-D band, whereas the smaller bands were 55,000 and 29,000 D, respectively. The incorporation of '251-MAB was blocked by the DA-l antagonist SCH-23390. The apparent molecular weight of the '251I-MAB binding sites obtained from solubilized PCT segments was similar in the WKY and SHR except that the 50,000-D band found in the WKY was absent or greatly reduced in intensity in the SHR when compared to the WKY (Fig. 8 A) .
Discussion
These studies show that the DA-1 agonists, fenoldopam, SKF-38393, and SND-919-C12 increase AC activity in the PCT of the WKY but not in the SHR despite similar DA-1 receptor density, affinity, and apparent molecular weight. This defect is selective since stimulation of AC activity in the PCT by other agents such as parathyroid hormone and forskolin are similar in WKY and SHR. Moreover, Guanyl nucleotides stimulated AC activity to a similar extent in WKY and SHR. Thus, these studies suggest that the decreased ability of DA-1 agonists to stimulate AC activity in the PCT of SHR is due to an altered DA-1 receptor-G protein coupling mechanisms. This is supported by the decreased ability of three different DA-l agonists to compete for specific '25I-SCH 23982 binding sites in the SHR. An aberrant DA-1 receptor-mediated cou- pling mechanism is supported also by the failure of the guanyl nucleotides, GTP and Gpp(NH)p, to enhance DA-I -mediated AC activity. The proposed DA-1 defect may not be related to gross abnormalities in the DA-1 receptor, since the molecular weight of the solubilized receptor is similar in the SHR and WKY. The high affinity (Kd = 220 pM) D-1 receptor photoaffinity probe, 1251-MAB (31) , was used to label a PCT dopamine binding site. '251I-MAB binding of the striatum of the WKY was included as a control. The apparent molecular weight of the major WKY and SHR PCT '25I-MAB binding site is similar to the central nervous system D-1 receptor found in bovine, canine, and porcine striatum (74,000 D) (31) . The smaller subunit of 50,000 D found in the PCT also has a similar molecular weight to a subunit found in the striatum (55,000 D).
There appears to be a reduction in the quantity of the 50,000-D subunit in the SHR when compared to the WKY. The significance ofthe 50,000-D subunit needs to be determined in future studies.
The 32,000-D subunit is unique to the PCT. Whether this represents a fundamental difference in the DA-1 receptor as compared to the central nervous system D-1 receptor or whether the 32,000-D subunit is a fragment of the 74,000-D subunit will have to be determined. This first demonstration of similar molecular weights between the central D-1 receptor and the peripheral DA-1 receptor is in concordance with other similarities of the central and peripheral dopamine receptors such as activation of AC through the Gs protein and a similar pharmacologic profile (29) .
Uncoupling defects exist for other cell membrane receptor systems coupled to AC stimulation. There is a striking similarity between the DA-1 defect described in the present study and the uncoupling of beta adrenergic receptors with AC in mouse S49 lymphoma cells described by Haga et al. (33) . In both cases there was failure of agonist-stimulated AC activity, guanyl nucleotide enhancement of agonist-stimulated AC activity, and reduced agonist affinity for the receptor. These defects have been found in the face of normal antagonist binding to the receptor. There are other examples of receptor AC uncoupling in pathologic states. For example, patients with pseudohypoparathyroidism can be subgrouped into categories based on the site of deficiency in the parathyroid hormone AC coupling (i.e., PTH hormone defect, pseudopseudohypoparathyroidism: Gs protein defect, pseudohypoparathyroidism type Ia). Some patients, however, present with normal parathyroid hormone receptors, Gs proteins, and AC activation through the Gs protein, yet demonstrate a gentically inherited receptor-AC coupling not unlike the DA-l defect found in the present study (pseudohypoparathyroidism type Ib) (35) . Similarly, insulin resistance in denervated rat skeletal muscle is a result ofa post receptor coupling defect (36) . As another example, addition of phospholipase C to plasma membranes from rat liver was associated with a loss of glucagon-stimulated AC activity and reduced agonist binding affinity compared with untreated membranes (37). These experiments suggested that the phospholipid microenvironment surrounding each receptor may influence agonist but not antagonist binding.
Abnormalities in the renal dopaminergic system have been reported in some animal models of hypertension (6, (21) (22) (23) (24) (25) (26) (38) (39) (40) . In young SHR where some have reported that renal tissue or urinary concentrations of DA are elevated (21, 23, 24) , sodium excretion is less in the young SHR than its normotensive WKY control (23, 41) . Inhibition of peripheral dopamine production by carbidopa decreased sodium excretion and accelerated the development of hypertension in the SHR (24). In the Dahl salt-sensitive rat, a decreased renal dopamine production is associated with a lesser sodium excretion than the Dahl salt-resistant rat (39) . Thus, aberrant renal DA concentrations and/or release can be found in experimental models of hypertension. Studies from our laboratory (6, 26) and others (25) have demonstrated possible physiologic consequences of an aberrant PCT DA-l receptor in the SHR. The intrarenal arterial infusion of the DA-1 agonist, SKF 38392 results in a diuresis and natriuresis in WKY but not SHR (26) .
There may also be a decreased natriuretic effect ofendogenous dopamine in SHR since the intrarenal arterial infusion of the DA-1 antagonist SCH 23390 decreased sodium excretion in WKY but not SHR (6) . Whether the aberrant DA concentrations and/or release are compensatory mechanisms to overcome a defective proximal tubular DA-1 receptor-coupling remains to be determined. The possibility that the DA-1 AC coupling is a primary defect is supported by our studies that demonstrate that the DA-I AC coupling defect is found in the 3-wk-old SHR and persists with the establishment of hypertension.
The existence of DA-l AC coupling defect has yet to be reported in human essential hypertension. However, there are evidences for a decreased renal action of DA-1 agonists in hypertensive subjects. A decreased natriuretic and renal vasodilator effect of DA-1 agonists has been described in some hypertensive patients (42) (43) (44) (45) . The natriuretic effect of fenoldopam (100 mg per os) measured by Carey et al. (43) was blunted in hypertensive patients when compared to normotensive subjects studied by Stote et al. (46) under similar experimental conditions. Defects in the renal dopaminergic system may be an inherited disorder. Some normotensive subjects with family history of hypertension have high urinary dopamine and lower sodium excretion compared with those without a family history of hypertension (45) .
The precise physiological consequence of an apparent DA-1 receptor-AC defect in the PCT, either permanent or temporary, remains to be determined. Although an increased sodium reabsorption in the superficial proximal tubule of SHR has not been reported (47) , other nephrons or nephron segments may be involved (48) . Lithium clearance studies have revealed increased reabsorption of sodium in proximal tubules of conscious SHR (48) . The Na+/H+ antiport activity in renal brush border membrane vesicles in SHR is apparently increased (49) . This is a possible site of expression of the DA-1-AC coupling defect in SHR, since AC may mediate the inhibitory effect of DA on this antiporter in WKY (14) . Whether the tendency for sodium retention in SHR that is aggravated when DA production is decreased (24) is due solely to this proximal tubular DA-1-AC defect remains to be determined. Na+/K'ATPase activity is also increased in the proximal tubule of the young SHR (50). The role of deeper or more distal segments of the nephron where dopamine receptors (17, 19) and effects (15, 16, 20) have been also demonstrated remains to be determined. However, there are reports of increased sodium transport in the proximal tubule of other genetic models of hypertension (51, 52). In the Dahl salt-sensitive rat, we have found (Kinoshita, S., and R. A. Felder, unpublished observations) that a DA-1 receptor-AC coupling defect is also present in the PCT of this strain. Bertorello and Aperia have reported that DA increased Na+/K+ATPase activity in PCT of Dahl salt-sensitive rat but had the opposite and expected effect in Dahl salt-resistant rat (40) . Dopamine may also decrease proximal sodium transport by inhibiting Na+/K+ATPase activity (1, 5, 11-13). Thus, it is possible that the DA-1 receptor defect in the SHR and Dahl salt-sensitive rat may play a role in the altered renal sodium transport in these models of hypertension.
In summary, we have shown that DA-1 receptor or G protein coupling is defective in the PCT of the SHR. This may represent an in vivo model of an uncoupled cell surface receptor that may contribute to the pathophysiology of hypertension in the SHR.
